# Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

> **NCT05953831** · PHASE2 · WITHDRAWN · sponsor: **Cardior Pharmaceuticals GmbH**

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** CDR132L
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05953831
- **Lead sponsor:** Cardior Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Transfer of study responsibility and planning
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05953831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05953831, "Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05953831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*